AD198 (AD) and DOX activated the PKC-δ pathway in tested K9TCC and K9OSA cell lines.
Notes: K9TCC#2-Dakota and K9OSA#1-Zoe cells were treated with 1 μM DOX and 1 μM AD for 24 hours. (A) CREB, PKC-δ (CF), p-p38, p38, p-CREB, p-ATF2, and CREB protein levels were detected by WBs. Actin was used as loading control. The results are representative of three independent experiments (n=3). (B) Densitometry evaluation of PKC-δ (CF), p-p38, p-ATF2, and p-CREB protein bands from WB analysis was done using ImageJ software. Values represent the mean of measured densitometry of each protein’s band from two replicates of three independent experiments ± standard error (n=6). Paired Student’s t-tests were used to compare controls to DOX and AD treatments (*P<0.05, **P<0.01, ***P<0.001) and to compare DOX to AD treatment (##P<0.01).
Abbreviations: AD, AD198; ATF2, activating transcription factor 2; PCK-δ (CF), cleaved fragment of PKC-δ; CREB, cyclic AMP response element binding protein; DOX, doxorubicin; K9OSA, canine osteosarcoma; K9TCC, canine transitional cell carcinoma; PKC-δ, protein kinase C-delta; WB, Western blot.